Diabetes in dogs: What you should know
了解犬糖尿病的症状和如何管理疾病。
Search
The different stages of your dog’s life
你的狗生活的不同阶段
Protecting our pets from parasites!
保护我们的宠物免受寄生虫的侵害！
Boehringer Ingelheim and Twist Bioscience Enter Therapeutic Antibody Discovery Collaboration
Boehringer Ingelheim and Twist Bioscience Enter Therapeutic Antibody Discovery Collaboration
Boehringer Ingelheim Focuses COVID-19 Clinical Research on Alteplase
Boehringer Ingelheim Focuses COVID-19 Clinical Research on Alteplase
Biomedical Data Science Fellowship Program with Yale
Biomedical Data Science Fellowship Program with Yale
Expansion of Collaboration with MD Anderson to Explore KRAS and TRAILR2 Compounds in Lung Cancer
Expansion of Collaboration with MD Anderson to Explore KRAS and TRAILR2 Compounds in Lung Cancer
Phase 2 Clinical Testing in NASH and Obesity
Phase 2 Clinical Testing in NASH and Obesity
Collaboration with the LIBD to Develop Centrally Acting COMT Inhibitors
Collaboration with the LIBD to Develop Centrally Acting COMT Inhibitors
Boehringer Ingelheim and Gubra Join Forces to Identify and Validate Innovative Peptides for the Treatment of Obesity
Boehringer Ingelheim and Gubra Join Forces to Identify and Validate Innovative Peptides for the Treatment of Obesity
Collaboration with Enara Bio on Cancer Immunotherapies
Collaboration with Enara Bio on Cancer Immunotherapies
Boehringer Ingelheim to acquire NBE-Therapeutics
Boehringer Ingelheim to acquire NBE-Therapeutics
Boehringer Ingelheim to acquire Labor Dr. Merk & Kollegen
Boehringer Ingelheim to acquire Labor Dr. Merk & Kollegen
Collaboration with Proxygen on Molecular Glue Degraders
Collaboration with Proxygen on Molecular Glue Degraders
Expanded alliance with OBT advances cancer immunology pipeline
Expanded alliance with OBT advances cancer immunology pipeline
Boehringer Ingelheim and Mirati Therapeutics Announce Clinical Collaboration to Study BI 1701963, a SOS1::pan-KRAS Inhibitor in Combination with MRTX849, a KRAS G12C Selective Inhibitor
Boehringer Ingelheim and Mirati Therapeutics Announce Clinical Collaboration to Study BI 1701963, a SOS1::pan-KRAS Inhibitor in Combination with MRTX849, a KRAS G12C Selective Inhibitor
Boehringer Ingelheim and Click Therapeutics Enter into Collaboration to Develop and Commercialize CT-155, a Novel Prescription Digital Therapeutic to Aid in the Treatment of Schizophrenia
Boehringer Ingelheim and Click Therapeutics Enter into Collaboration to Develop and Commercialize CT-155, a Novel Prescription Digital Therapeutic to Aid in the Treatment of Schizophrenia
Boehringer Ingelheim discontinues development of BI 1467335 for Diabetic Retinopathy
Boehringer Ingelheim discontinues development of BI 1467335 for Diabetic Retinopathy
Numab Therapeutics and Boehringer Ingelheim Enter into Collaboration to Develop Multi-specific Antibody Therapeutics for Cancer and Retinal Diseases
Numab Therapeutics and Boehringer Ingelheim Enter into Collaboration to Develop Multi-specific Antibody Therapeutics for Cancer and Retinal Diseases
New consortium EUbOPEN will provide tools to unlock disease biology
New consortium EUbOPEN will provide tools to unlock disease biology
Boehringer Ingelheim Acquires Northern Biologics’ Preclinical Cancer Antibody Pipeline, Expanding Immuno-oncology Portfolio
Boehringer Ingelheim Acquires Northern Biologics’ Preclinical Cancer Antibody Pipeline, Expanding Immuno-oncology Portfolio
Boehringer Ingelheim Collaborates with CDR-Life to Develop Antibody Fragment-based Therapeutics for Geographic Atrophy, a Leading Cause of Blindness Worldwide
Boehringer Ingelheim Collaborates with CDR-Life to Develop Antibody Fragment-based Therapeutics for Geographic Atrophy, a Leading Cause of Blindness Worldwide
Boehringer Ingelheim Enters Discovery Stage Collaboration with Trutino Biosciences to Grow Its Cancer Immunology Portfolio with Novel Cytokine Platform
Boehringer Ingelheim Enters Discovery Stage Collaboration with Trutino Biosciences to Grow Its Cancer Immunology Portfolio with Novel Cytokine Platform
Boehringer Ingelheim Partners with Enleofen to Develop First-in-Class Anti-IL-11 Therapies for a Range of Fibrotic Diseases
Boehringer Ingelheim Partners with Enleofen to Develop First-in-Class Anti-IL-11 Therapies for a Range of Fibrotic Diseases
Boehringer Ingelheim discontinues development of BI 1467335 for NASH
Boehringer Ingelheim discontinues development of BI 1467335 for NASH